Anti-PD-1 antibodies
AssigneeShanghai Henlius Biotech, Inc.
InventorsWeidong Jiang, Pei-Hua Lin, Chi-Ling Tseng
Life of this patent
Estimating the term…
Abstract
Provided are anti-PD-1 antibodies, and antigen binding fragments thereof. Also provided are isolated nucleic acid molecules that encode the anti-PD-1 antibodies or antigen binding fragments thereof, related expression vectors, and host cells. Provided are methods of making anti-PD-1 antibodies, and antigen binding fragments thereof. Also provided are related pharmaceutical compositions and methods of their use to treat subjects. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present disclosure.
Claims15
One or more isolated nucleic acid molecule(s) encoding an anti-PD-1 antibody that comprises:
- (a) a light chain variable domain (VL) sequence comprising (1) a CDR-L1 comprising the amino acid sequence KASQDVTTAVA (SEQ ID NO:9);
- (2) a CDR-L2 comprising the amino acid sequence WASTRHT (SEQ ID NO:10);
- and (3) a CDR-L3 comprising the amino acid sequence QQHYTIPWT (SEQ ID NO:11), and a heavy chain variable domain (VH) sequence comprising:
- (1) a CDR-H1 comprising the amino acid sequence FTFSNYGMS (SEQ ID NO:12);
- (2) a CDR-H2 comprising the amino acid sequence TISGGGSNIY (SEQ ID NO:13);
- and (3) a CDR-H3 comprising the amino acid sequence VSYYYGIDF (SEQ ID NO:14);
- (b) a light chain variable domain (VL) sequence comprising (1) a CDR-L1 comprising the amino acid sequence KASTDVTTAVA (SEQ ID NO:15);
- (2) a CDR-L2 comprising the amino acid sequence WASLRHT (SEQ ID NO:16);
- and (3) a CDR-L3 comprising the amino acid sequence QQHYGIPWT (SEQ ID NO:17), and a heavy chain variable domain (VH) sequence comprising (1) a CDR-H1 comprising the amino acid sequence FRFSNYGMS (SEQ ID NO:18);
- (2) a CDR-H2 comprising the amino acid sequence TISGGGSNAY (SEQ ID NO:19);
- and (3) a CDR-H3 comprising the amino acid sequence TSYYYGIDF (SEQ ID NO:20);
- (c) a light chain variable domain (VL) sequence comprising (1) a CDR-L1 comprising the amino acid sequence KAKQDVTTAVA (SEQ ID NO:21);
- (2) a CDR-L2 comprising the amino acid sequence WASTRHT (SEQ ID NO:10);
- and (3) a CDR-L3 comprising the amino acid sequence QQHYWIPWT (SEQ ID NO:22), and a heavy chain variable (VH) domain sequence comprising (1) a CDR-H1 comprising the amino acid sequence FTFSNYGMS (SEQ ID NO:12);
- (2) a CDR-H2 comprising the amino acid sequence TISGGGSNIY (SEQ ID NO:13);
- and (3) a CDR-H3 comprising the amino acid sequence VSYYYGIDL (SEQ ID NO:23);
- or
- (d) a light chain variable domain (VL) sequence comprising (1) a CDR-L1 comprising the amino acid sequence KASQDVTNAVA (SEQ ID NO:24);
- (2) a CDR-L2 comprising the amino acid sequence WASTRHT (SEQ ID NO:10);
- and (3) a CDR-L3 comprising the amino acid sequence QQHYTIPWT (SEQ ID NO:11), and a heavy chain variable domain (VH) sequence comprising (1) a CDR-H1 comprising the amino acid sequence FTFSNYGMS (SEQ ID NO:12);
- (2) a CDR-H2 comprising the amino acid sequence TISGGGSNIY (SEQ ID NO:13);
- and (3) a CDR-H3 comprising the amino acid sequence SSYYYGIDL (SEQ ID NO:25).
Dependencies are inferred from the claim text.